Background— Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …

In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an
orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for …

Rationale: The relationship between the initial treatment strategy and survival in pulmonary
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival …

Objectives: To examine baseline characteristics and outcome, and to determine variables
affecting survival in patients with pulmonary arterial hypertension (PAH) associated with HIV …

Recent data suggest that inflammatory processes play a major role in pulmonary vascular
remodelling in patients with idiopathic, heritable, and drug-or toxin-induced (ihd) pulmonary …

Background & Aims Long-term outcomes in portopulmonary hypertension (PoPH) are poorly
studied in the current era of pulmonary hypertension management. We analysed the effect …

Aims The present role of echocardiography is generally restricted to screening for pulmonary
arterial hypertension (PAH). The aim of our study was to identify new echocardiographic …

Bosentan has proven 4-month efficacy in patients with HIV-associated pulmonary arterial
hypertension (PAH-HIV). Herein, the long-term outcome of unselected PAH-HIV patients …

Pulmonary veno-occlusive disease (PVOD) carries a poor prognosis and lung transplantation
is the only curative treatment. In PVOD, epoprostenol therapy is controversial, as this …

There are conflicting data regarding the magnitude and determinants of chronic obstructive
pulmonary disease (COPD) risk in farmers. In a cross-sectional study of 917 nonfarming …